An open-label, multicenter, phase II single arm trial of osimertinib in non-small cell lung cancer patients with uncommon EGFR mutation (KCSG-LU15–09) - Ahn, M-J; Cho, J H; Sun, J-M (J Clin Oncol, 2018)
, et al.